Biotechs Ready To Roar

The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector for many reasons.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.